drugset / Trial / NCT01842451

A Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of VX-135 and Daclatasvir in Subjects With Genotype 1 Chronic Hepatitis C Chronic Hepatitis C

NCT01842451

Phase 2 Completed 23 enrolled Vertex Pharmaceuticals Incorporated
RandomizedParallel-groupDouble-blindTreatment

Summary

A Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of VX-135 and Daclatasvir in Treatment-Naïve Adult Subjects With Genotype 1 Chronic Hepatitis C

Timeline

Start
2013-06
Primary completion
2014-05
Completion
2014-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Daclatasvir Small molecule
Subject VX-135 Small molecule